Head-To-Head Survey: MiNK Therapeutics (NASDAQ:INKT) vs. Genocea Biosciences (NASDAQ:GNCAQ)

Genocea Biosciences (NASDAQ:GNCAQ – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Profitability

This table compares Genocea Biosciences and MiNK Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
MiNK Therapeutics	N/A	-665.42%	-109.70%

Analyst Ratings

This is a summary of recent ratings and target prices for Genocea Biosciences and MiNK Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0	0	0	0	N/A
MiNK Therapeutics	0	0	3	0	3.00

MiNK Therapeutics has a consensus target price of $5.00, indicating a potential upside of 140.38%.

Earnings & Valuation

This table compares Genocea Biosciences and MiNK Therapeutics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.64 million	0.00	-$33.20 million	N/A	N/A
MiNK Therapeutics	N/A	N/A	-$27.99 million	($0.77)	-2.70

MiNK Therapeutics has lower revenue, but higher earnings than Genocea Biosciences.

Institutional & Insider Ownership

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 1.4% of MiNK Therapeutics shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 13.2% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Genocea Biosciences has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.61, indicating that its share price is 161% less volatile than the S&P 500.

About Genocea Biosciences

(Get Rating)

Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

About MiNK Therapeutics

(Get Rating)

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.